DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics
company, today announced that it will present five data posters at
the American Association of Cancer Research (AACR) Annual Meeting
2023, which convenes in Orlando, Florida from April 14-19, 2023.
The presentations will focus on how XNA can be used to improve
the assay sensitivity of different technology platforms such as
Sanger sequencing, qPCR, and Next Generation Sequencing (NGS).
DiaCarta’s XNA technology has demonstrated improvements to the
sensitivity of traditional Sanger sequencing to comparable
sensitivity levels of NGS, with much broader clinical utility and
lower cost. The XNA-based Sanger sequencing and qPCR are used for
sensitive companion diagnostics (CDx) assay development for
identification of KRAS G12C mutation. The critical mutation
currently has two targeting drugs, LUMAKRAS™ (sotorasib) and
KRAZATI™ (adagrasib), approved by the FDA for target therapy on
patients with locally advanced or metastatic Non-Small Cell Lung
Cancer (NSCLC) with KRAS G12C mutation.
“We can leverage our cost-effective XNA
technology for ultra-sensitive assay development, which is critical
for early cancer detection and cancer recurrence monitoring,” said
Dr. Aiguo (Adam) Zhang, CEO and President of DiaCarta, Inc. “Our
technology has great potential to be used for minimal residual
disease (MRD) monitoring of residual cancer cells after initial
treatment and cancer clonal recurrence. MRD monitoring is the trend
for precision diagnostics and monitoring in cancer management. The
current ultra-deep sequencing technology used in MRD is both time
consuming and costly and our technology has the potential to
overcome these two obstacles.”
Details of the AACR poster presentations
are as follows:
Title: Detection of actionable lung cancer
fusion genes with known and novel partners from highly degraded
FFPE materialAbstract #: 2191 /
1Session: Diagnostic and Prognostic Biomarkers
2Date/Time: April 17, 2023, 9:00 AM – 12:30 PM
(ET)Location: Section 41
Title: Detection of tumor-associated
methylation and mutation signatures for early colorectal cancer
diagnosisAbstract #: 2302 /
16Session: Liquid Biopsies: Circulating Nucleic
Acids and Circulating Tumor Cells 2Date / Time:
April 17, 2023, 9:00 AM – 12:30 PM (ET)Location:
Section 44
Title: Two detection methods of clinical KRAS
G12C mutation detection for companion diagnosticsAbstract
#: 3298 / 6Session: Diagnostic and
Prognostic Biomarkers 3Date / Time: April 17,
2023, 1:30 PM – 5:00 PM (ET)Location: Section
41
Title: ColoScape test: a molecular assay to
detect early-stage colorectal cancer in plasma cell-free
DNAAbstract #: 6505 / 3Session:
Early Detection and Molecular Markers of PreventionDate /
Time: April 19, 2023, 9:00 AM – 12:30 PM
(ET)Location: Section 28
Title: XNA increases assay
sensitivity in sanger sequencing, qPCR, NGS and CRISPR mutant
screeningAbstract #: 6681 /
1Session: Liquid Biopsies: Circulating Nucleic
Acids and Circulating Tumor Cells 5Date / Time:
April 19, 2023, 9:00 AM – 12:30 PM (ET)Location:
Section 40
The posters will also be available on DiaCarta’s
website following the presentations.
About DiaCartaDiaCarta is a
molecular diagnostics company that has developed innovative
technologies to transform patient care by providing effective
precision diagnostics using liquid biopsy. Its novel XNA technology
is designed to provide a high level of sensitivity as it binds to
the wild-type sequence, to enable only the mutant target sequence
to be amplified. Using this technology, DiaCarta has developed its
ColoScape™ colorectal cancer mutation test. Powered by its
isorbDNA™ technology that amplifies the signal and requires no
RNA/DNA extraction or amplification, DiaCarta has developed its
RadTox™ test to personalize radiation and chemotherapy, mitigate
adverse events and enhance patient care. Based in Pleasanton,
California, DiaCarta is ISO certified, GMP-compliant, and offers
CLIA certified laboratory services to its
customers. www.diacarta.com
On October 14, 2022, DiaCarta and HH&L
Acquisition Co. (NYSE: HHLA), a special purpose acquisition
corporation, entered into a definitive business combination
agreement that would result in DiaCarta becoming a public
company.
Important Additional Information Will Be Filed with the
SEC
This communication relates to the proposed business combination
between HH&L and DiaCarta (the “Business Combination”).
HH&L has filed a preliminary, and will file a definitive, proxy
statement, which will include a prospectus, which will be a part of
a registration statement, and other relevant documents with the
SEC. This communication does not contain all the information that
should be considered concerning the proposed Business Combination
and is not intended to form the basis of any investment decision or
any other decision in respect of the Business Combination.
HH&L’s and DiaCarta’s shareholders and other interested persons
are urged to read the proxy statement/prospectus and any other
relevant documents filed with the SEC when they become available,
and any amendments thereto, because, among other things, they will
contain updates to the financial, industry and other information
herein as well as important information about HH&L, DiaCarta
and the contemplated Business Combination. When available, the
definitive proxy statement/prospectus and other relevant materials
for the proposed Business Combination will be mailed to
shareholders of HH&L as of a record date to be established for
voting on the proposed Business Combination. Shareholders will be
able to obtain a free copy of the proxy statement/prospectus (when
filed), as well as other filings containing information about
HH&L, DiaCarta and the proposed Business Combination, without
charge, at the SEC’s website located at www.sec.gov or by directing
a request to: HH&L Acquisition Co., Suite 2001-2002, 20/F, York
House, The Landmark, 15 Queen’s Road Central, Central, Hong Kong.
Investment in any securities described herein has not been approved
or disapproved by the SEC or any other regulatory authority nor has
any authority passed upon or endorsed the merits of the Business
Combination or the accuracy or adequacy of the information
contained herein. Any representation to the contrary is a criminal
offense.
Forward-Looking Statements
This communication contains certain statements, estimates,
targets, forecasts, and projections with respect to HH&L or
DiaCarta. All statements other than statements of historical fact
are forward-looking statements. Forward-looking statements include,
without limitation, statements regarding the estimated future
financial performance and financial position of DiaCarta. Future
results are not possible to predict. Opinions and estimates offered
in this communication constitute DiaCarta’s judgment and are
subject to change without notice, as are statements about market
trends, which are based on current market conditions. You can
identify these forward looking statements through the use of words
such as “may,” “will,” “can,” “anticipate,” “assume,” “should,”
“indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,”
“estimate,” “continue,” “plan,” “point to,” “project,” “predict,”
“could,” “intend,” “target,” “potential” and other similar words
and expressions of the future, but the absence of these words does
not necessarily mean that a statement is not forward-looking. Such
forward-looking statements are based on estimates, assumptions and
factors that are inherently uncertain, that are beyond DiaCarta’s
control or ability to predict and that could cause actual results
to differ materially from expected results. As a result, they are
subject to significant risks and uncertainties and actual events or
results may differ materially from these forward-looking
statements. No reliance should be placed on any forward-looking
statements, including any projections, targets, estimates or
forecasts contained in this communication. Any forward-looking
statement speaks only as of the date on which it was made, based on
information available as of the date of this communication, and
such information may be inaccurate or incomplete. Products
described by DiaCarta in its pipeline are under investigation and
have not been proven to be safe or effective, and there is no
guarantee any such product will be approved in the sought-after
indication or will meet the developmental milestones set forth
herein, including within the timeline set forth herein. Neither
DiaCarta nor HH&L undertakes any obligation to release any
revisions to such forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by law. Information regarding performance by, or businesses
associated with, our management team or businesses associated with
them is presented for informational purposes only. Past performance
by DiaCarta’s management team and its affiliates is not a guarantee
of future performance. Therefore, you should not rely on the
historical record of the performance of DiaCarta’s management team
or businesses associated with them as indicative of DiaCarta’s
future performance of an investment or the returns DiaCarta will,
or is likely to, generate going forward.
Participants in the Solicitation
HH&L and its directors and executive officers may be deemed
to be participants in the solicitation of proxies from HH&L’s
shareholders in connection with the proposed Business Combination.
A list of the names of HH&L’s directors and executive officers
and information regarding their interests in HH&L is contained
in HH&L’s Annual Report on Form 10-K, which was filed with the
SEC on March 30, 2022, and is available free of charge at the SEC’s
website at www.sec.gov, or by directing a request to HH&L
Acquisition Co., Suite 2001-2002, 20/F, York House, The Landmark,
15 Queen’s Road Central, Central, Hong Kong. Additional information
regarding the interests of any such participants will be contained
in the proxy statement/prospectus for the proposed Business
Combination when available.
DiaCarta and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
shareholders of HH&L in connection with the proposed Business
Combination. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
Business Combination will be included in the proxy
statement/prospectus for the proposed Business Combination when
available.
The definitive proxy statement/prospectus will be mailed to
shareholders as of a record date to be established for voting on
the proposed Business Combination when it becomes available.
Shareholders, potential investors and other interested persons
should read the proxy statement/prospectus carefully when it
becomes available before making any voting or investment
decisions.
No Offer or Solicitation
This communication is for informational purposes only and does
not constitute (i) a solicitation of a proxy, consent or
authorization with respect to any securities or in respect of the
Business Combination, (ii) an offer or invitation for the sale or
purchase of the securities, assets or business described herein or
a commitment of HH&L, DiaCarta or any of their respective
subsidiaries, stockholders, affiliates, representatives, partners,
directors, officers, employees, advisers or agents, with respect to
any of the foregoing, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction, and this press release
shall not form the basis of any contract, commitment or investment
decision and does not constitute either advice or recommendation
regarding any securities.
Company Contact:Anne Vallerga PhD, MBAVP, External
Affairsannek@diacarta.com
PR Contact:Jennifer SparanoVP, Public
Relationsjsparano@peregrinemarketaccess.com
Investor Contact:Cody Slach, Matthew HauschGateway Group, Inc.
(949) 574-3860DiaCarta@GatewayIR.com
HH&L Acquisition (NYSE:HHLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
HH&L Acquisition (NYSE:HHLA)
Historical Stock Chart
From Sep 2023 to Sep 2024